<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Commercialization of Novel Assays for COVID-19 Therapeutics

Posted by MD Biosciences

Find me on:
on Sep 15, 2020 11:39:11 AM

Our team is excited to announce that we have signed an agreement in partnership with IncellDx, Inc., a global leader in single-cell diagnostics, to evaluate therapeutic biomarkers in COVID-19 and other cytokine storm conditions.


With our esoteric immune-based testing, we will validate and offer lab testing in the United States and European Union to measure levels of COVID/cytokine storm-related therapeutics. "Such cytokines are significantly elevated in patients with COVID-19, and usually remain abnormal in recovering patients, but still are suffering from symptoms. These patients are referred to as 'long-haulers' (PR News Centre, 2020)". 


To read the full article published by PR News Centre, follow the link below and learn more. 

Learn More

How can MD Biosciences support your clinical programs? Please contact our team with any questions, we are happy to speak with you! 

Email Us

+1 (651) 641-1770


Topics: Inflammation, Biomarkers, Personalized medicine, CLIA, Cytokines, clinical research, clinical diagnostics, COVID-19